Lars Fransecky

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 354 citations

Medicine, Hematology, Pharmacology +17

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Christoph Röllig, Michael Krämer, Christoph Schliemann et al. · Blood · 2020 · 135 citations · Full text

Medicine, Hematology, Oncology +7

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia

Lars Fransecky, Liliana H. Mochmann, Claudia D. Baldus · Molecular and Cellular Therapies · 2015 · 126 citations · Full text

Medicine, Oncology, Pharmacology +14

FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors

Martín Neumann, Ebru İnci Çoşkun, Lars Fransecky et al. · PLoS ONE · 2013 · 108 citations · Full text

Medicine, Molecular Biology, Oncology +14

Midostaurin plus intensive chemotherapy for younger and older patients with AML and <i>FLT3</i> internal tandem duplications

Hartmut Döhner, Daniela Weber, Julia Krzykalla et al. · Blood Advances · 2022 · 70 citations · Full text

Medicine, Hematology, Oncology +14